| __timestamp | Teva Pharmaceutical Industries Limited | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5078000000 | 5496000 |
| Thursday, January 1, 2015 | 4717000000 | 9786000 |
| Friday, January 1, 2016 | 5096000000 | 6792000 |
| Sunday, January 1, 2017 | 4986000000 | 7313000 |
| Monday, January 1, 2018 | 4214000000 | 8382000 |
| Tuesday, January 1, 2019 | 3806000000 | 10803000 |
| Wednesday, January 1, 2020 | 3671000000 | 12944000 |
| Friday, January 1, 2021 | 3528000000 | 21967000 |
| Saturday, January 1, 2022 | 3445000000 | 32810000 |
| Sunday, January 1, 2023 | 3498000000 | 46542000 |
| Monday, January 1, 2024 | 3702000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Teva Pharmaceutical Industries Limited, a giant in the generic drug market, has seen its Selling, General, and Administrative (SG&A) expenses decline by approximately 32% from 2014 to 2023. This reduction reflects strategic cost management amidst challenging market conditions. In contrast, Xenon Pharmaceuticals Inc., a smaller biotech firm, has experienced a staggering 747% increase in SG&A expenses over the same period, indicative of its aggressive growth and expansion strategies.
Teva's SG&A expenses peaked in 2016, while Xenon's expenses have consistently risen, reaching their highest in 2023. This divergence highlights the contrasting paths of a mature pharmaceutical leader and an emerging biotech innovator. As the industry continues to transform, these financial trends offer valuable insights into the strategic priorities and market positioning of these companies.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.